Pitango VC, established in 1993, is Israel's largest venture capital fund with over $2.8 billion under management. [citation needed] Pitango VC invests through three dedicated funds, Pitango First (early-stage investments), Pitango HealthTech (HealthTech investments), and Pitango Growth (growth investments). Pitango invests in startups around the world, in domains such as Vertical SaaS, Digital Health, Deep Tech, FinTech & InsureTech, Devops, Generative AI, Web3, and FoodTech.
With two offices in Israel (Herzliya and Sarona), Pitango currently manages several venture funds totaling over $2.8 billion in committed capital. It has invested in more than 250 companies with its investors including Time Warner, Citigroup, Eastman Kodak, Deutsche Bank and HarbourVest Partners.[1]
History
The fund was founded as Polaris Venture Capital in 1993 by Rami Kalish, as part of a government initiative named the Yozma program ("Initiative" in Hebrew); which offered attractive tax incentives to any foreign venture-capital investments in Israel and offered to double any investment with funds from the government.[2]
In 1996, Kalish was joined by Chemi Peres, son of former Israeli president Shimon Peres, to create Polaris Fund II, which raised more than $100 million. Polaris II invested in 35 high-tech companies. Some were partially funded by another Israeli VC firm, Eucalyptus Ventures. When the investments proved successful, Polaris II and Eucalyptus merged into Fund III in early 2000.[1]
In 2001, Polaris Venture Capital changed its name to Pitango Venture Capital, to avoid confusion with Boston based Polaris Venture Partners. Although the Boston firm was founded in 1996, which was after Pitango was founded, the Israeli firm decided to change its name. Pitango takes its name from the semi-wild Surinam Cherry that grows in Israel.[3]
Pitango Venture Capital Fund IV followed in 2004, and in 2007, Pitango V.[citation needed]
In 2010, with the support of the Israeli government, Pitango established the first fund in the country focused on investment in the Arab-Israeli sector, called Al-Bawader (Arabic for “early signs”).[4]
^Cohen, Omri (7 February 2007). "Biotech comes of age: Bioline floats at half-billion shekel market cap". TheMarker. Retrieved 28 November 2011. Bioline Therapeutics today pulled off its initial public offering in Tel Aviv, raising NIS 211 million at a company valuation of NIS 494 million, making this the biggest flotation by a biotechnology company in local history.
^Rheinheimer, Laura (8 February 2007). "BioLineRx raises $50m. in TASE's largest biomedical IPO". Jerusalem Post. Retrieved 28 November 2011. BioLineRx Ltd. on Wednesday priced the largest ever initial public offering of a biomedical company on the Tel Aviv Stock Exchange, raising a total of NIS 211 million, or $50m.